On November 8, 2024, Director Lawson Macartney sold 2,000 shares of Viking Therapeutics Inc (VKTX, Financial) at a price of $68.67 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 47,965 shares of the company.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company's lead clinical program, VK5211, is being evaluated for the treatment of patients recovering from non-elective hip fracture surgery.
Over the past year, the insider transaction history for Viking Therapeutics Inc shows a trend of more insider selling than buying. There have been 23 insider sells and no insider buys. Specifically, Lawson Macartney has sold a total of 2,000 shares and has not purchased any shares during this period.
On the day of the sale, Viking Therapeutics Inc shares were trading at $68.67, giving the company a market cap of approximately $7.63 billion. This valuation reflects the company's position and ongoing developments within the biopharmaceutical sector.
For further insights into Viking Therapeutics Inc's valuation metrics such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can refer to the GF Value for a comprehensive analysis.
This insider sale might be of interest to current and potential investors trying to understand market trends and the actions of company insiders. It is essential to consider such transactions within the broader context of market conditions, company performance, and individual investment strategies.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
